Destiny Breast04
Patient-reported outcomes from DESTINY-Breast04
2:01
DESTINY-Breast04: practice-changing results for HER2-low breast cancer
1:08
DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer
0:56
DESTINY-Breast04: T-DXd for patients with HER2-low mBC
4:18
ASCO 2022: DESTINY-Breast04, PALOMA-2, rEECur
6:33
Detailed safety analysis from the DESTINY-Breast04 trial
2:31
DESTINY-Breast04: T-DXd in HER2-low breast cancer regardless of molecular markers
3:31
ASCO Daily News 2022 Plenary Update - LBA3: DESTINY-Breast04
5:11
DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC
3:02
Destiny-Breast04: Expanding T-DXd to HER2-Low
2:33
DESTINY-Breast Trials: Expanding Treatment Horizons
3:28
DESTINY-Breast04 Study: T-DXd Breakthrough for HER2-Low Breast Cancer Treatment
4:51
Destiny-Breast04 Trial
1:14
DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancer
0:45
Biomarker-based personalization for HER2-low breast cancer treatment in DESTINY-Breast04
1:28
DESTINY Breast 04 Data and How It Impacts the Current Pathology Landscape